Febrikast-LC Syrup is a combination medication containing Levocetirizine (2.5mg/5ml) and Montelukast (4mg/5ml), formulated to provide effective relief from allergic conditions. Levocetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, runny nose, itchy or watery eyes, and urticaria by blocking the action of histamine. Montelukast, a leukotriene receptor antagonist, works by preventing leukotrienes from binding to their receptors in the lungs and airways, which helps decrease inflammation, bronchoconstriction, and mucus production commonly associated with asthma and allergic rhinitis. The synergistic action of these two active ingredients makes Febrikast-LC Syrup particularly useful in managing seasonal allergic rhinitis, perennial allergic rhinitis, and mild to moderate asthma in pediatric and adult patients. It is generally well-tolerated, with minimal side effects such as mild drowsiness or gastrointestinal discomfort. Febrikast-LC Syrup should be used under medical supervision, especially in patients with liver or kidney impairment. This combination offers a convenient and effective approach to controlling allergy symptoms and improving respiratory health, enhancing the quality of life for individuals suffering from allergic disorders.